Introduction
Actions of circulating angiotensin II (Ang II) within the central nervous system (CNS) play a critical role in Ang II-induced hypertension. 1 Elevated plasma Ang II can act on neurons in circumventricular organs in the forebrain located outside the blood-brain barrier. [2] [3] [4] Angiotensinergic projections from the circumventicular organs can relay the signals of circulating Ang II to neurons in the paraventricular nucleus (PVN), supraoptic nucleus (SON) and rostral ventrolateral medulla (RVLM) 5, 6 and thereby increase sympathetic nerve activity (SNA), 5, 7, 8 as well as plasma vasopressin, 9 aldosterone and endogenous ouabain (EO). 10, 11 Chronically, circulating and brain Ang II also activate a neuromodulatory pathway involving aldosterone-mineralocorticoid receptors (MR)-epithelial sodium channels (ENaC)-EO and a2 Na þ pumps. 12, 13 This pathway enhances the effectiveness of Ang II-Ang type 1 receptor (AT 1 R) signalling in, e.g. the PVN and is essential for persistent increases in SNA, 14 plasma aldosterone and EO, 10, 11 and the chronic hypertension. 10 Ang II-induced hypertension is markedly amplified by a high salt (HS) diet. 15, 16 This HS-induced amplification involves central actions of Ang II. 17, 18 For example, CNS pathways involving the PVN are necessary to maintain SNA and elevated blood pressure (BP) in Ang II þ HS hypertension. 19, 20 Chronic increases in plasma/CSF [Ang II] or [Na þ ] both activate the MR-ENaC-EO neuromodulatory pathway. 12 Therefore, simultaneous increases in plasma Ang II and dietary salt might enhance the activity of the aldosterone-MR-ENaC-EO-AT 1 R pathway in the CNS significantly more than low-dose Ang II alone. In support of this concept, chronic intracerebroventricular (icv) infusion of the ENaC blocker, benzamil, prevents Ang II þ HS induced hypertension 21 ; suggesting that brain ENaCs may play an important role. Secondly, these central pathways enhance effective sympathetic tone 16, 22 by increasing peripheral key slow-pressor mechanisms involving plasma aldosterone as well as EO and its effects on arterial Ca 2þ -transporters. 23 To test the aforementioned hypotheses, we assessed in Wistar rats; (i) the effects of infusion of sc Ang II at the minimally effective dose of 150 ng/kg/min, alone or combined with HS on BP, plasma and tissue aldosterone and EO and the arterial calcium transport protein, Na þ /Ca 2þ exchanger-1 (NCX1), and
(ii) the effects of chronic icv infusion of an MR antagonist, ENaC blocker or AT 1 R blocker on these parameters in rats with Ang II þ HS hypertension.
The results reveal that the severe hypertension caused by the combination of a minor increase in plasma Ang II and a HS intake depends largely upon a pathway that involves MR-ENaC-AT 1 R in the CNS. Stimulation of this CNS pathway activates a humoral axis that increases circulating aldosterone and EO, and arterial myocyte NCX1 protein expression.
Methods

Animals
Male Wistar rats weighing 200-250 g were obtained from Charles River Breeding Laboratories (Montreal, PQ, Canada), housed on a 12 h light/dark cycle at constant room temperature, and provided with a standard laboratory chow (0.4% NaCl, RS) and tap water ad libitum. All surgeries and experiments for the present study were approved by the University of Ottawa Animal Care Committee and conform with the Guide for the Care and Use of Laboratory Animals published by the US National Institute of Health (11th Edition, 2011). For all surgeries, rats were anesthetized with 2% isoflurane in oxygen. Effective levels of anesthesia were maintained by observing reactions to physical stimulation such as toe-pinch, as well as monitoring the pattern of respiration. For pain relief, sustained release buprenorphine (1 mg/kg) was injected subcutaneously (sc) 1 h before surgery, which provides adequate analgesia for 3 days.
Ang II-salt model of hypertension
Wistar rats were placed on high salt diet (2% NaCl, HS), or continued regular salt (0.4% NaCl, RS) and the same day infusion of Ang II was started at a dose of 150 ng/kg/min sc by osmotic minipump (Model 2002, ALZET, DURECT Corp, Cupertino, CA, USA). This dose of Ang II was adopted from other studies 16, 21 and causes only a minimal increase in plasma Ang II levels. 24 All experiments were performed in male rats, because female rats exhibit marked attenuation of the hypertension induced by Ang II. 25 Different sets of animals were used according to the following protocols.
Protocol I: effects of AngII-HS on BP, plasma and tissue aldosterone and EO
An initial experiment was performed to obtain primary data for the Ang II-HS model. Three groups of rats were used (n = 4-6 per group) for measurements of BP, plasma Ang II, and plasma and tissue aldosterone and corticosterone. One group stayed on RS and two groups were fed HS; one of the latter also received a sc infusion of Ang II for 2 weeks. For the main experiment, two subsets of animals were studied (first and second study of first experiment). In the first study, four groups of rats were used for BP and heart rate (HR), plasma Ang II, plasma and tissue aldosterone, corticosterone and EO. Groups 1 and 2 (n = 6) stayed on RS, whereas groups 3 and 4 (n = 8) were placed on HS. Groups 2 and 4 also were infused sc with Ang II for 2 weeks. Sham surgery was done for groups 1 and 3, without implantation of a pump. Body weight (BW) was measured at the start and at the end of the treatment and 24 h water intake at the end of week 1 and 2 of treatment. In a follow-up study, the same groups were studied to assess effects on BP and aldosterone as well as plasma electrolytes and adrenal mRNA and proteins. An additional fifth group was included for HS þ sc vehicle. Results for this group were the same as for HS alone (data not shown).
In the morning of days 12-13 of the Ang II infusion, the right femoral artery was cannulated with a PE-50/10 tubing filled with heparinized saline (1000 U/ml in 0.9% NaCl). After recovery for 2-3 h, arterial lines were connected to a pressure transducer linked to a data acquisition system. Digital signals of BP and HR were processed by a personal computer equipped with Acknowledge 3. 8 . After a 20-30 min rest, resting BP and HR were recorded for 20 min. In rats of the follow-up experiment, 1 ml arterial blood was collected for measurement of plasma electrolytes by ion-selective electrode (Roche/Hitachi "Cobas C" system, Roche Diagnostics, Laval, QC, Canada). Rats then were returned to original cages and kept in a quiet room until the next morning. The conscious rats were rapidly decapitated in order to obtain sufficient trunk blood for plasma Ang II, aldosterone, corticosterone and EO without causing ACTH release. The heart was rapidly removed, rinsed in ice-cold saline, and the right ventricle (RV) was separated from the left ventricle (LV), blotted and weighed. In the first study of the main experiment, the aortas were then removed and placed in ice-cold physiological salt solution. The aortas were cleaned of fat and connective tissue, de-endothelialized and frozen in liquid nitrogen. Adrenals were collected for CYP11B1 (11-b-hydroxylase gene) and CYP11B2 (aldosterone synthase gene) mRNA expression levels and kidneys for EO levels. Adrenal protein expression levels were measured in the follow-up experiment. All tissues were stored at -80 C until used.
Protocol II: effects of central blockades on Ang II-salt induced hypertension
Under anesthesia, a telemetry transmitter (model TA11PA-C40; DSI-St. Paul, MN, USA) was placed into the abdominal cavity and secured to the ventral abdominal wall with the catheter inserted into the abdominal aorta. The telemetry signal was transmitted, wirelessly, to a receiver placed under the cage, connected to a data acquisition system to record BP and HR. Data collection was initiated 5 days after surgery using Scheduled Sampling Mode with a 1 min recording duration at the beginning of each hour. After recording baseline BP and HR for 2 days, icv cannulae and osmotic minipumps (Model 2004, ALZET) were implanted for chronic icv infusion in eight groups of rats with n = 5-6/group for the four active treatment groups, and n = 3/group for four control groups. All responses were similar in the four vehicle groups that were therefore combined. across the groups exhibited transmitter or icv cannula dysfunction, and data from these rats were excluded. Rats were allocated to the following treatments: (1) MR blocker, eplerenone (10 lg/kg/day, in aCSF with 4% acetonitrile); (2) MR blocker, spironolactone (10 lg/kg/day in aCSF with 2% ethanol); (3) ENaC blocker, benzamil (4 mg/kg/h, in aCSF with 15% propylene glycol); (4) AT 1 R blocker, losartan (1 mg/kg/day, in aCSF); and groups 5-8) controls (the vehicles for groups 1-3 respectively, and aCSF for group (4) all at an infusion rate of 0.25 ll/h. The doses of the various antagonists were based on previous studies. Eplerenone is specific for MR but has low affinity, whereas spironolactone has high affinity but is not specific for MR. However, responses to the 2 MR blockers were similar as shown for the BP in Figure 1B , and other results for the 2 MR blockers were combined. Two days after the start of icv infusions, all rats were fed HS and infused sc with Ang II at 150 ng/kg/min. BW and water intake were recorded at the start and at the end of the 2 week infusion period. At the end, trunk blood was collected for plasma Ang II, aldosterone, corticosterone and EO, and heart, adrenals and kidneys were collected. 
Biochemical assays for Ang II, aldosterone, corticosterone and EO
The whole hypothalamus and hippocampus were dissected according to Glowinski and Iversen. 27 Aldosterone and corticosterone were measured by radioimmunoassay (RIA) as described previously. 10 For the standard curve of the aldosterone assay, the lowest detectable value was 0.5 pg per tube. Since the average weight of hypothalamic tissue was 80--90 mg and the amount in each RIA tube was 14 mg, the sensitivity for hypothalamic aldosterone was 0.5/14 = 35 pg/g. The average weight for the hippocampus was 180--190 mg, the amount in each RIA tube was 36 mg, and the sensitivity was 0.5/36 = 14 pg/g. Observed levels of hypothalamic and hippocampus aldosterone (>50 pg/g) were higher than the detection limit. The aldosterone antibody (MP Biomedicals, NY, USA; product #07-108216) exhibits <0.1% cross-reactivity with other steroids. Corticosterone was determined using a corticosterone 125 I RIA kit (MP Biomedicals, NY, USA; product #07-120103). Plasma Ang II concentrations were measured by RIA after extraction on C18 Sep-Pak cartridges and separation by HPLC as previously described. 9 For EO, all plasma samples were first subjected to solid phase extraction (SPE). Tissue samples were weighed, homogenized in methanolwater mixtures, vacuum dried and extracted using C18 columns (200 mg, Bond Elut, Agilent Technologies, Santa Clara, CA, USA). Routine SPE-RIA was used; reconstituted samples were employed in duplicate for ouabain RIA using the R7 antiserum described previously. 28 All measurements were made blind with coded samples.
Immunoblotting for arterial and adrenal proteins
Arterial proteins
Membrane proteins were solubilized in sodium dodecyl sulfate buffer containing 5% 2-mercaptoethanol and separated by polyacrylamide gel electrophoresis. The blot was incubated overnight at 4 C with mouse monoclonal anti-NCX1 (R3F1, diluted 1: 500; a generous gift from Dr. K.D. Philipson, UCLA, USA). Gel loading was controlled with monoclonal anti-b actin antibodies (dilution 1:10 000; SigmaAldrich, St. Louis, MO, USA). After washing, membranes were incubated with anti-rabbit horseradish peroxidase (HRP)-conjugated IgG for 1 h at room temperature. The immune complexes on the membranes were detected by Enhanced Chemiluminescence Plus' (Amersham Biosciences, Piscataway, NJ, USA) and exposure to X-ray film (Eastman Kodak, Rochester, NY, USA). Quantitative analysis of immunoblots was performed by using a Kodak DC120 digital camera and 1 D Image Analysis Software (Eastman Kodak). NCX1 immunoblots usually show prominent bands at 120 and 70 kDa, often with a less prominent band at 160 kDa that is normally ignored. In non-reducing gels (b-mercaptoethanol omitted), the 160 kDa band is usually more prominent than the 120 kDa band. 29 Nevertheless, the various treatments generally affect the relative densities of the 160 and 120 kDa bands in similar fashion. Chymotrypsin decreases the density of both large bands and increases that of the 70 kDa band, suggesting that the 70 kDa band is a proteolytic fragment. 29 In the experiment of protocol I, for reasons that are not clear, the immunoblot behaved like a non-reducing gel (i.e. as if b-mercaptoethanol had been omitted). The 160 kDa band was analyzed for protocol I, and the 120 kDa band for protocol II to minimize the variance in each of the analyses.
Adrenal proteins
Adrenal cortex was homogenized in lysis buffer (50 mM Tris-HCl, pH 7.4; 1% Nonidet P-40; 0.25% sodium deoxycholate; 150 mM NaCl; 1 mM EDTA; 1 mM phenylmethylsulfonyl fluoride; 1 mM Na3VO4, 1 mM NaF plus 1% of protease inhibitor cocktail (Sigma) for protein extraction. 40 lg proteins were separated by a 10% SDS-PAGE gel. 
Statistical analysis
Values are expressed as mean ± SE. increase in plasma Ang II levels ( Table 1) . As expected, 2 weeks of HS alone had little effect on MAP, while sc infusion of Ang II alone increased BP modestly, for MAP from 99 ± 1 to 108 ± 2 mm Hg, as measured by intra-arterial line ( Figure 1A) . Systolic, but not diastolic BP increased significantly ( Table 1) . In contrast, the combination of Ang II with HS increased MAP markedly to 160 ±6 mmHg in the preliminary experiment and to 152 ±4 mmHg in the main experiment ( Figure 1A) . Both systolic and diastolic BP increased by 50% and LV weight increased significantly ( Table 1) . None of the treatments affected HR, RV weight or BW gain ( Table 2) . HS alone modestly increased water intake but more combined with Ang II ( Table 2) . Plasma Na þ , K þ and Cl -did not change ( 
Plasma Ang II (pg/ml) 24 ± 6 18 ± 4 24 ± 2 14 ± 5
Systolic BP (mmHg) 
Values are means ± SE. For HR, BW gain and water intake, n = 12-16/group (2 studies combined). For RV weight, n = 8-13/group (preliminary experiment þ first study of first experiment). For Na þ , K þ and Cl -, n = 6-10/group. HR, heart rate;RV, right ventricle; BW, body weight. *P < 0.05 vs. others. **P < 0.05 vs. regular salt.
.
3.2
Low-dose Ang II with high salt diet increases plasma and tissue aldosterone, corticosterone and EO
Plasma hormone levels and adrenal gene expression
Ang II activates and HS decreases steroid synthesis in the adrenal cortex. Therefore, we measured the mRNA and protein levels of two key steroid biosynthetic enzymes and the plasma levels of three adrenal steroids. Two weeks of HS alone had a negligible effect on CYP11B1 mRNA and protein ( Table 3 ) but caused a marked decrease in CYP11B2 mRNA (Figure 2A) . The decline in CYP11B2 mRNA was associated with only minor (NS) decreases in CYP11B2 protein ( Figure 2C and D) and plasma aldosterone ( Figure 3A) .
Ang II with or without HS had no effect on CYP11B1 mRNA and protein (Table 3 ) but significantly increased CYP11B2 mRNA and protein (Figure 2A and D) . In rats on RS, sc infusion of Ang II did not change plasma corticosterone (Table 3) , or EO ( Figure 3B ) and caused a modest (NS) increase in plasma aldosterone ( Figure 3A) . Despite similar changes in adrenal gene expression, the combination of Ang II þ HS caused a distinctly different pattern of changes in the levels of the 3 plasma steroids than Ang II or HS alone. Ang II þ HS increased plasma aldosterone by four-fold ( Figure 3A, Table 3 ), corticosterone by two-fold (Table 3) and EO by two-fold ( Figure 3B) . Increases in plasma corticosterone and aldosterone showed highly significant correlations ( Figure 4A ).
Tissue hormone levels
Because Ang II also activates a steroid pathway in the brain, 10 we also measured brain aldosterone and corticosterone. Indeed, whereas Ang II þ RS caused only modest (NS) increases, low-dose sc Ang II þ HS significantly increased aldosterone levels in the hypothalamus and the hippocampus four-fold and corticosterone levels nearly 10-fold ( Table 3) . Plasma and hypothalamus levels for each of the two steroids correlated significantly ( Figure 4B, C) . In addition, hypothalamic corticosterone and aldosterone levels are correlated significantly ( Figure 4D ). Since circulating ouabain/EO can accumulate in the kidney, 31, 32 we assessed the effects of Ang II and HS on renal EO levels. Whereas HS alone had no effect on renal EO levels, Ang II alone or together with HS, increased the renal EO content up to three-fold ( Table 4) .
NCX1 expression in the aorta
In many models of hypertension, including icv Ang II-induced hypertension, NCX1 and several other arterial myocyte Ca 2þ transporter proteins are markedly up-regulated. 11 ,33 HS or low-dose sc Ang II alone caused a minor increase in NCX1 protein. In contrast, Ang II þ HS increased myocyte NCX1 by >two-fold compared to controls ( Figure 5B ). 
Central MR-ENaC
Plasma aldosterone (pg/ml) 179 ± 84* 41 ± 9 69 ± 31 44 ± 13
Plasma corticosterone (ng/ml) 108 ± 35 72 ± 24 113 ± 57 53 ± 17
Values are means ± SE.
Top panel:
Values for hypothalamus and hippocampus aldosterone and corticosterone, n = 6-8/group (second study of first experiment); for plasma aldosterone, n = 12-16/group for two studies combined; for plasma corticosterone, n = 8-12/group (preliminary experiment þ first study of first experiment); for CYP11B1/PGK1, n = 11-14/group (two studies combined), and for CYP11B1/b-actin, n = 5-6/group (second study of first experiment). 
Hormonal responses to CNS pathway blockade
All the icv blockers reduced adrenal CYP11B2 mRNA expression ( Figure 2B ) but had no effect on CYP11B1 mRNA ( Table 3) . The reductions in adrenal CYP11B2 were all reflected by reduced plasma aldosterone levels in sc Ang II þ HS-treated rats ( Figure 3C) . The lack of effect of the icv blockers on plasma corticosterone ( Table 3 , bottom panel) fits with the unaltered adrenal CYP11B1. Furthermore, plasma EO in the Ang II þ HS rats was significantly reduced by all the icv blockers ( Figure 3D ). This decline in plasma EO likely accounts for the reduction of renal medullary EO in the presence of the icv blockers ( Table 4 , bottom panel), because renal medullary EO is often a reflection of the plasma level. 32 
Cardiovascular responses to CNS pathway blockade
The combination of sc Ang II (150 ng/kg/min) with 2% HS and icv vehicles increased MAP by 50 mm Hg after 10 days ( Figure 1B ) and similarly increased systolic and diastolic BP ( Table 1) . Concurrent icv infusion of eplerenone, spironolactone, benzamil or losartan prevented most of the increase in MAP ( Figure 1B) as well as the increase in LV weight ( Table 1) . The blockers also greatly reduced aortic NCX1 protein expression relative to that in Ang II þ HS with vehicles ( Figure 5C ). The icv blockers caused a minor (NS) decrease in water intake (end of first week: 24 ± 4 vs. 18 ± 2 ml/100 g BW, t = 1.7, p = 0.1; end of second week: 21 ± 2 vs. 17 ± 1 ml/100 g BW, t = 1.6, p = 0.1, vehicles vs. combined blockers).
Discussion
The present study provides two major new findings regarding the pathophysiology of Ang II þ HS hypertension in rats, a model for salt-sensitive essential hypertension. 15, 16, 34 First, the gradual development of severe hypertension by the combination of a low-dose infusion of Ang II given in the periphery, and a modest increase in salt intake depends critically on a CNS pathway involving MR-ENaC-AT 1 R signalling. Second, in addition to the well-established CNS-mediated increase in sympathetic activity, 16, 34 activation of this CNS pathway also increases plasma aldosterone and EO, and arterial NCX1 protein expression. Together, the elevated aldosterone and EO likely amplify sympathetic actions on the kidneys and arteries.
A novel CNS neurohumoral pathway mediates Ang II þ salt hypertension
The synergy between circulating Ang II and high dietary salt in the elevation of BP is well documented in humans, 35 dogs 15, 36 and rodents. 37, 38 We employed the low-dose Ang II þ HS model to elucidate central and peripheral mechanisms that mediate the elevation of BP.
As reported previously, 24 sc infusion of Ang II at the low dose of 150 ng/kg/min does not cause a detectable increase in plasma Ang II and causes only a minor increase in BP. When combined with a 2% salt diet, however, this same Ang II infusion rate induces severe hypertension and significantly increases LV weight. The extent of these effects is similar to the effect of infusing sc Ang II at the high rate of 500 ng/kg/min in rats on a regular (0.4%) salt diet. 24 Moreover, in both the low-dose Ang II þ HS and the high-dose Ang II þ RS models, central AT 1 R blockade prevents or reverses most of the hypertension (present study and Refs. 14 and 39). This indicates that the activation of central angiotensinergic pathways by circulating Ang II, either with or without HS, plays a critical role in the pathogenesis of the hypertension. Central MR or ENaC blockade also prevents/reverses most of the hypertension in the high-dose Ang II þ RS and low-dose Ang II þ HS models (present study, Refs. 10, 14, 21, 39, 40) . This implies that the same CNS MR-ENaC-AT 1 R pathway contributes to the hypertension in both models. Both Ang II and [Na þ ] can activate this pathway, 12 and their effects are synergistic. 36, 37 Thus, it is not surprising that a high dietary salt intake, that, by itself, has little effect on BP, can augment the A B C D Figure 3 Sc infusion of Ang II at 150 ng/kg/min significantly increases plasma aldosterone and EO in rats on high salt (HS) diet but not in rats on regular salt (RS) diet (panels A and B). Central infusion of an MR blocker (eplerenone or spironolactone), ENaC blocker (benzamil) or AT 1 R blocker (losartan) significantly lowers plasma aldosterone and EO in rats with Ang II on HS diet (panels C and D). Panels A and B: values are means ± SE (for plasma aldosterone, n = 12-16/group for 2 studies combined; for plasma EO, n = 6-8/group). Two-way ANOVA: *P<0.05 vs. others. Panels C and D: values are means ± SE. Veh, n = 11 for plasma aldosterone and n = 6 for plasma EO, MR inh, n = 9 for plasma aldosterone and n = 6 for plasma EO, benzamil (Ben), n = 6 and losartan (Los), n = 4. Student t-test for Veh vs. blockers combined. *P< _0.05 vs. others. In the first experiment (panels A and B), blood samples were obtained after recent surgery, likely explaining the higher values for plasma aldosterone, EO and corticosterone ( 
CNS neurohumoral pathwaydependent regulation of plasma aldosterone and EO
Sc infusion of Ang II in rats on regular dietary salt doubled the adrenal CYP11B2 mRNA and protein levels but caused only a modest (NS) increase in plasma aldosterone, suggesting that net enzymatic activity of the aldosterone synthase increased only minimally. In contrast, the high (2%) salt diet alone decreased plasma Ang II, adrenal CYP11B2 mRNA and protein and plasma aldosterone, as expected. 45 Nevertheless, the A B C D Figure 5 Sc Ang II at 150 ng/kg/min significantly increases NCX1 protein in the aorta of rats on 2% high salt (HS), but not in rats on regular salt (RS) diet (panels A and B). Central infusion of an MR blocker (eplerenone or spironolactone), ENaC blocker (benzamil) or AT 1 R blocker (losartan) prevents the increase in NCX1 protein in the aorta caused by Ang II in rats on HS diet (panels C and D). Panels A and B: the summary data are for changes in NCX1 relative to the control group. A representative immunoblot shows 160 kDa NCX1 protein under non-reducing conditions. Values are means ± SE (n = 5-8/group). Two-way ANOVA: *P<0.05 vs. others. Panels C and D: the summary data are for changes in NCX1 protein levels relative to the vehicle; n = 6 for vehicle (Veh), n = 6 for MR blocker, n = 6 for benzamil (Ben), and n = 4 for losartan (Los [50] [51] [52] These explanations seem especially plausible because all blockers of the CNS neurohumoral pathway suppressed elevation of CYP11B2 mRNA ( Figure 2B ), plasma aldosterone ( Figure 3C ) and plasma EO ( Figure 3D ).
There is extensive evidence for the synthesis of ouabain and other cardiotonic steroids in both the CNS and adrenals. 11, 53 CNS EO via secretion of EO, possibly by the pituitary can be a source of circulating EO. 11 Adrenal production and secretion of EO is generally considered the major source of plasma EO 50, 54 and can be stimulated by ACTH, Ang II and catecholamines. 55 Further, activation of the hypothalamic aldosterone-MR-ENaC pathway by, e.g. Ang II or salt, 11, 55, 56 increases hypothalamic EO, and may, thereby, also contribute to the elevated plasma EO. 57 The parallel elevation of plasma aldosterone and EO in Ang II þ HS hypertension ( Figure 3A and B) and in a large portion of patients with essential hypertension that are also salt-sensitive 58 suggests a common link in their regulation and biosynthesis.
CNS-mediated actions of Ang II þ HS on peripheral pressor mechanisms
If SNA, rather than Ang II, directly activates arterial myocytes and is primarily responsible for the elevated vascular tone in Ang II þ HS hypertension, 44 we must ask whether the SNA alone, mediates the BP , an increase in the Ca 2þ stored in the sarcoplasmic reticulum (SR), and an amplification of Ca 2þ signalling (the acute 'vasotonic effect'). When the EO/ouabain elevation is sustained, it also activates a protein kinase signalling cascade that includes C-Src. This induces an increase in the expression of several arterial Ca 2þ transporter proteins, including NCX type 1 (NCX1, Figure 5 ) and the SR Ca 2þ pump, SERCA2. 11, 32, 59 The net effect of this chronic action of EO is a further amplification of Ca 2þ signalling in response to vasoconstrictors such as SNA. These considerations imply that, in addition to SNA, the CNS neuromodulatory pathway signals to the arteries via circulating EO, and that arterial a2 Na þ pumps and NCX1 also may play a crucial role in chronic BP elevation. Experimental support for this view comes from studies on mice with genetically engineered arterial a 2 Na þ pumps and NCX1 and mice in which EO is immuno-neutralized. Mice with reduced smooth muscle (SM)-specific a2 Na þ pump expression (i.e. fewer than normal EO receptors) have elevated basal BP and enhanced sensitivity to Ang IIand HS-induced BP elevation. 60 Also, mice with SM-specific overexpression of NCX1 are hypertensive and exhibit enhanced sensitivity to HS
(Ang II was not tested). 61 Finally, in Ang II þ HS hypertensive mice, BP can be reduced by "DigiFab" (fab fragments that selectively immunoneutralize EO). [62] [63] [64] These reports, plus the present results and data from icv Ang II-infused rats, 11 suggest that chronic activation of CNS mechanisms by Ang II þ HS causes hypertension in part by amplifying the effective sympathetic tone via EO-dependent reprogramming of arterial function. This peripheral effect of EO would enable minimal increases in sympathetic drive to sustain high BP.
Limitations
The present study provides novel evidence that central mechanisms mediate the strong synergistic actions of dietary salt and circulating Ang II. However, the mechanisms and specific locations within the CNS by which high dietary salt intake amplifies the central actions of Ang II require further studies. Central infusions of different blockers were performed to assess the functional role of the brain MR-ENaC-AT 1 R pathway. The 2 MR blockers combined and the AT 1 R blocker provide specific evidence for the role of brain MR and AT 1 R. On the other hand, benzamil can affect several Na þ -channels or transporters, 65 but as discussed previously 26 at the current infusion rate likely causes primarily ENaC blockade. The aldosterone antibody exhibits low cross-reactivity for other steroids (0.04% for corticosterone). However, the concentration of corticosterone is in the ng range vs. pg for aldosterone. Thus, 100 ng/ml or ng/g of corticosterone would be measured as 40 pg/ml or pg/g of "aldosterone" in the aldosterone RIA. However, comparison of the absolute levels and their changes by Ang II þ HS (Table 3) indicates that most of the RIA values indeed reflect aldosterone per se. 6 . Clinical perspectives 6 
.1 Pathophysiology
Under normal physiological conditions, the imposition of low or high salt diets either enhances or diminishes, respectively, the circulating levels of Ang II, aldosterone and EO with little net effect on BP. The animal model of moderate high salt intake combined with a minimal increase in plasma Ang II bears a striking resemblance to those patients with salt-sensitive essential hypertension in whom plasma renin activity is marginally increased and the circulating levels of EO and aldosterone are co-elevated. 58 The inability to suppress Ang II on high salt intake results in an increase in plasma aldosterone and EO and rather severe hypertension. All of these effects depend critically on activation of a CNS pathway that involves MR-ENaC-AT 1 R signalling ( Figure 6 ). This central pathway increases SNA, per se, but, in addition, apparently requires the participation of circulating EO and peripheral pressor mechanisms that enhance the effect of sympathetic tone on the arteries in order to effect chronic BP elevation ( Figure 6 ). The CNS can stimulate adrenocortical steroid production via a mediator that is likely to be independent of ACTH or Ang II. Although the identity of this mediator is not known, it could underlie the subtle adrenocortical dysfunction in patients with essential hypertension. 66 ,67
Therapeutic implications
If similar CNS pathways also play a role in patients with, e.g. salt-sensitive hypertension, obviously central infusions are not a relevant treatment strategy, and the key question is whether oral treatment is able to target
this CNS signalling pathway. A number of animal studies have demonstrated that oral treatment with MR or AT 1 R blockers can cause substantial central blockade and can prevent salt-induced hypertension. 68 In humans, oral treatment can lower sympathetic hyperactivity, consistent with central actions. 69, 70 Moreover, aminopeptidase A (APA) inhibitors such as RB150, can cross the BBB and inhibit conversion of Ang II to Ang III in the CNS. They are presently being tested in clinical studies as a new class of antihypertensive drugs to specifically target the brain RAS.
71,72
Figure 6 Proposed central and peripheral pathways/mechanisms being activated by circulating Ang II and high dietary salt intake.
Central components: Both circulating Ang II and dietary salt, presumably by (transiently) increasing plasma [Na þ ], can activate Ang II-AT 1 R-ROS signaling in circumventricular organs such as the SFO and OVLT which are located outside of the BBB, followed by activation of angiotensinergic projections to the PVN, SON and RVLM (red lines). Prolonged stimulation of AT 1 R -MR in the SFO also activates a slow neuromodulatory pathway (box at upper right) that involves locally in the hypothalamus produced aldosterone that binds MR in, e.g. SON and PVN and via ENaC increases hypothalamic EO. Ouabain or EO acutely inhibit a2 Na þ pumps and chronically also activate an a2 Na þ pump associated protein kinase cascade that increases expression of ACE, AT 1 R and NADPH oxidase subunits. As a consequence, chronic Ang II-AT 1 R-ROS signaling is maintained/enhanced. Peripheral components: Chronic activation of brain angiotensinergic pathways can cause a persistent increase in sympathetic tone and in addition may stimulate the production and secretion of CNS EO as well as of AVP and ACTH into the circulation. These factors can all contribute to enhanced adrenal production and secretion of aldosterone, corticosterone and EO. A chronic increase in plasma EO will activate an a2 Na þ pump-associated protein kinase cascade (e.g. C-Src-mediated) that increases arterial smooth muscle cell NCX expression, and arterial sarcoplasmic reticulum (SR) Ca 2þ pump (SERCA2) expression. The EO-induced NCX and SERCA2 up-regulation enhances Ca 2þ signaling and thereby effects of SNA to increase vascular tone and elevate BP.
